Why the study?
Do different moxonidine-based combination therapies improve blood pressure and target organ damage in patients with metabolic syndrome and Stage 1-2 arterial hypertension?
Do different moxonidine-based combination therapies improve blood pressure and target organ damage in patients with metabolic syndrome and Stage 1-2 arterial hypertension?
Moxonidine combined with amlodipine or enalapril effectively lowers blood pressure and improves cardiac and renal parameters in patients with metabolic syndrome, whereas combination with hydrochlorothiazide may negatively affect renal function.
No takes yet. Share an insight, caveat, or question.
Moxonidine plus amlodipine or enalapril achieves higher BP control rates than hydrochlorothiazide combination; extends optimized regimen options in metabolic syndrome hypertension.
Тишина et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: